Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
The interplay between the intestinal microbiota and the brain.
New multiple sclerosis phenotypic classification.
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Natalizumab Use During the Third Trimester of Pregnancy.
Biogen Idec receives negative opinion from the CHMP on Fampyra
The two faces of neuromyelitis optica.
Gordon Research Conference on Immunochemistry & Immunobiology
Uhthoff's phenomena in MS-clinical features and pathophysiology.
Patient reported outcome measures in neurogenic bladder.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Novel therapies for memory cells in autoimmune diseases.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.

Pages